Esperion Therapeutics Inc (NASDAQ:ESPR) — Market Cap & Net Worth
Market Cap & Net Worth: Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc (NASDAQ:ESPR) has a market capitalization of $726.75 Million ($726.75 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10178 globally and #2726 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Esperion Therapeutics Inc's stock price $3.18 by its total outstanding shares 239063437 (239.06 Million). See capital reinvestment ratio of Esperion Therapeutics Inc to understand how much of operating cash flow is reinvested back into capital assets.
Esperion Therapeutics Inc Market Cap History: 2015 to 2026
Esperion Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $5.32 Billion to $760.22 Million (-17.00% CAGR).
Index Memberships
Esperion Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.03% | #284 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1061 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.04% | #169 of 263 |
Weight: Esperion Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Esperion Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Esperion Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.58x
Esperion Therapeutics Inc's market cap is 1.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $11.00 Billion | $184.47 Million | -$201.81 Million | 59.61x | N/A |
| 2019 | $14.26 Billion | $148.36 Million | -$97.17 Million | 96.08x | N/A |
| 2020 | $6.22 Billion | $227.55 Million | -$143.55 Million | 27.32x | N/A |
| 2021 | $1.20 Billion | $78.45 Million | -$269.11 Million | 15.24x | N/A |
| 2022 | $1.49 Billion | $75.47 Million | -$233.66 Million | 19.73x | N/A |
| 2023 | $714.80 Million | $116.33 Million | -$209.25 Million | 6.14x | N/A |
| 2024 | $525.94 Million | $332.31 Million | -$51.74 Million | 1.58x | N/A |
Competitor Companies of ESPR by Market Capitalization
Companies near Esperion Therapeutics Inc in the global market cap rankings as of August 3, 2026.
Key companies related to Esperion Therapeutics Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Esperion Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Esperion Therapeutics Inc's market cap moved from $5.32 Billion to $ 760.22 Million, with a yearly change of -17.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $760.22 Million | -14.05% |
| 2025 | $884.53 Million | +68.18% |
| 2024 | $525.94 Million | -26.42% |
| 2023 | $714.80 Million | -52.01% |
| 2022 | $1.49 Billion | +24.60% |
| 2021 | $1.20 Billion | -80.77% |
| 2020 | $6.22 Billion | -56.40% |
| 2019 | $14.26 Billion | +29.63% |
| 2018 | $11.00 Billion | -30.13% |
| 2017 | $15.74 Billion | +425.88% |
| 2016 | $2.99 Billion | -43.76% |
| 2015 | $5.32 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Esperion Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $726.75 Million USD |
| MoneyControl | $726.75 Million USD |
| MarketWatch | $726.75 Million USD |
| marketcap.company | $726.75 Million USD |
| Reuters | $726.75 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more